What MACI does that simpler cartilage repairs cannot

The answer to why MACI involves two procedures rather than one comes down to tissue quality.

Simpler techniques such as microfracture work by penetrating the bone beneath a cartilage defect so that marrow cells bleed into the gap. Those cells form a patch, but it is fibrocartilage — a mechanically inferior scar tissue. Published evidence suggests this repair tissue can begin to break down at around two to three years; in some cases the deterioration progresses to osteoarthritis, making any future intervention more difficult.

MACI takes a different route. A small sample of the patient's own cartilage cells (chondrocytes) is harvested arthroscopically and sent to a laboratory, where they are expanded over four to six weeks and seeded onto a porcine type I/III collagen membrane. When that membrane is implanted, the cells mature into hyaline-like repair tissue — closer in structure and mechanics to native articular cartilage than fibrocartilage scar.

The membrane also addresses a technical limitation of first-generation autologous chondrocyte implantation (ACI), which required harvesting a periosteal patch to contain the cells. The collagen scaffold distributes cells more evenly and removes that additional surgical step. MACI received FDA approval in 2016; the underlying two-stage cell-based principle has a longer clinical evidence trail in Europe.

That biological advantage is real — and it is also what makes patient selection so important.

Who is a genuine candidate

Candidacy for MACI rests on a fairly specific combination of factors — damage that is deep enough and focal enough, a joint that is otherwise sound, and a patient who can commit to a demanding recovery.

The core picture: deep, focal, and isolated

Full-thickness damage — rated Grade III or IV on the ICRS scale, meaning the cartilage is worn through to or close to bone — is the starting point. The damage also needs to be focal rather than spread across multiple compartments. Widespread, degenerative joint disease falls outside the indication; MACI addresses a discrete lesion, not a globally worn joint.

Approved locations include the femoral condyle, trochlea, patella, and tibia. The underlying cause matters less than the nature of the defect: osteochondritis dissecans (OCD), osteonecrosis, post-traumatic injury, and localised osteoarthritis are all recognised pathways to the same qualifying defect type. Where a cavitary bone deficiency measures more than 8 mm in depth, this too can fall within the indication.

Defect size is arguably the sharpest single selector. For lesions reaching approximately 3 cm² or larger, the published evidence — including randomised trial data — points most clearly in MACI's favour over older marrow-stimulation techniques. For smaller defects, single-stage options such as OATS or AMIC may offer comparable results with less procedural complexity (the outcome data behind that size threshold are covered in the evidence section).

Age and the 55-year boundary

Formal approval runs from age 18 to 55. It is worth being direct about what that upper limit means: safety and efficacy above 55 have not been established, which reflects a gap in the evidence rather than a certainty that the procedure fails beyond that age. For patients in their late fifties or older, a consultant assessment is still worthwhile — alternative cartilage-restoration options may be appropriate depending on the clinical picture.

A mechanically sound joint is non-negotiable

Ligament instability and malalignment both compromise graft survival. Where a significant varus or valgus deformity is loading the affected compartment, a corrective osteotomy (such as an HTO or DFO) is carried out at the same time as or before implantation. The joint needs to be properly aligned for the repair to hold.

Who is not suitable

Clear exclusions include generalised osteoarthritis, inflammatory arthritis (such as rheumatoid or psoriatic), and active joint infection — none of which represent the focal, otherwise stable environment the procedure requires. An equally practical exclusion is an inability to follow post-operative rehabilitation: the recovery protocol is structured and extended, and adherence to it is part of what determines whether the repair matures correctly.

The two stages and what recovery involves

MACI asks for a genuine commitment before the first procedure begins and for many months after the second. Understanding both stages makes that commitment concrete.

Stage 1 is a short arthroscopic day-case. A small sample of healthy cartilage cells is taken from a low-load area of the knee, then sent to Vericel's laboratory. Over approximately four to six weeks, those cells are expanded in culture and seeded onto the porcine collagen membrane — the scaffold that will carry them back into the joint.

Stage 2 is the implantation itself, and it is a more involved operation than Stage 1. A mini-arthrotomy — a small open incision rather than further keyhole access — is required to prepare the defect and fix the cell-loaded membrane in place with fibrin sealant. This stage typically requires a short inpatient admission rather than a day-case.

After implantation, the repair tissue matures gradually into hyaline-like cartilage over 12 to 18 months. That biological timeline is worth taking seriously: symptom improvement is real but incremental, and the full functional benefit generally emerges well into the second year rather than in the early post-operative period.

Weight-bearing restrictions in the weeks following surgery are strict. This is not a standard precaution — inability to comply with rehabilitation is listed as a formal exclusion criterion, because poor load management during the maturation window is a recognised route to graft failure. A pre-operative consultation will set out each phase of the protocol in detail.

What the long-term evidence actually shows

Survival and satisfaction figures at ten years sit at roughly 75–90% across published series — a strong return for any surgical cartilage procedure, and one that matters when the long-term alternative for many patients in this age group is eventual joint replacement.

The patellofemoral evidence adds useful granularity. A prospective study of 82 patients — 41 patellar and 41 trochlear — recorded outcomes at two, five, and ten or more years. KOOS, SF-36, and VAS pain and severity scores all improved significantly at the longest follow-up (p<0.05), with no meaningful difference in results between the two anatomical sites.

The SUMMIT comparison in perspective

The randomised trial against microfracture showed superior KOOS pain and function scores at two and five years — and the persistence of that advantage to five years is the more informative finding. Fibrocartilage repair tissue, produced by microfracture, tends to degrade as time passes. That the performance gap remained measurable at five years is consistent with a more durable biological repair rather than simply an earlier recovery. For smaller defects, the evidence does not point as clearly in MACI's favour, and single-stage options such as AMIC may offer comparable results with less procedural complexity.

Two years versus the longer picture

A 2025 matched-pair analysis comparing MACI, AMIC, and minced cartilage — 16 patients per group — found no statistically significant differences between techniques at two years; all three produced meaningful reductions in pain and improvements in KOOS function scores. At that follow-up horizon, MACI offers no demonstrable advantage over these alternatives. The differentiation is most clearly supported in larger defects and at longer follow-up.

Honest evidence gaps

Head-to-head comparisons between MACI and osteochondral allograft beyond five years are limited — a genuine gap in the evidence base. The regulatory upper age boundary of 55 reflects the absence of trial data for older patients rather than a confirmed finding of harm; that population remains without clear evidence-based guidance.

Side effects in the early post-operative period commonly include joint pain, swelling, and effusion. Less frequent but more serious risks include graft failure and osteoarthritis progression.

Cost and accessing MACI privately in the UK

Private access to MACI in the UK involves two distinct cost layers. The laboratory step — expansion and seeding of the chondrocyte cells onto the collagen membrane — accounts for approximately £9,000 to £11,000 of the total. Add surgical fees, anaesthesia, a short inpatient admission for the Stage 2 implantation, and post-operative physiotherapy, and the realistic range for a complete episode of private care typically sits between £18,000 and £25,000 or more, depending on facility and surgeon. (American research figures cited in the literature reach $70,000 at the upper end; those reflect US facility and insurer pricing structures rather than UK private practice norms.)

A UK health-economic analysis calculated a lifetime incremental cost-effectiveness ratio of £4,360 per quality-adjusted life year gained relative to microfracture — well beneath the NICE reference threshold of £20,000–£30,000 per QALY. Despite the high upfront cost, the long-run case in carefully selected patients compares favourably when measured in quality-of-life terms.

NHS commissioning for MACI is limited and varies considerably by integrated care board; most patients access it through private orthopaedic practice or on a self-pay basis. Those with private medical insurance should confirm coverage and pre-authorisation requirements directly with their insurer before proceeding, as policy terms differ meaningfully.

MSK Doctors consultants can review existing imaging and assess candidacy at the Grantham and Sleaford sites without a GP referral.

How MACI fits alongside other cartilage repair options

Microfracture held first-line status for small defects for many years — its historical role is real, but as discussed earlier in this article, the fibrocartilage it produces is prone to breakdown, and the damage it causes to the subchondral bone plate can complicate any subsequent repair. It is no longer a modern first choice.

AMIC adds a collagen scaffold over the microfracture site, recruiting the patient's own progenitor cells into the matrix in a single stage. For defects up to roughly 3–4 cm², short-term outcomes match MACI's — a 2025 matched-pair analysis (n=16 per group) found no statistically significant difference between the two at two years. MACI's clearest advantage is in larger defects and at longer follow-up, where the SUMMIT data are most persuasive.

OATS and mosaicplasty transfer small plugs of intact bone and cartilage from a low-load area to the defect in a single stage — best suited to lesions of 1–4 cm², with donor-site morbidity at the harvest area as the principal trade-off.

For larger or post-traumatic defects where autograft volume is insufficient, osteochondral allograft (OCA) uses donor tissue and carries long-term follow-up data in defects that exceed MACI's practical size range.

Where malalignment is present, osteotomy (HTO or DFO) must precede or accompany any cartilage repair — MACI included. No restoration technique holds up reliably in a mechanically overloaded compartment.

For patients with smaller focal lesions who prefer to avoid theatre, the ChondroFiller injection offers an ultrasound-guided outpatient injectable collagen scaffold pathway — a distinct treatment category, not a surgical alternative to MACI.

As a practical guide: a 4 cm² femoral condyle defect in a 35-year-old sits squarely in MACI's evidence base; a 1.5 cm² isolated lesion in a 40-year-old makes AMIC a reasonable starting point; a 7 cm² post-traumatic lesion is more likely to point towards OCA. Defect geometry, bone quality, and broader joint health are what an MSK Doctors consultant maps against those categories at first assessment.

1. [1] Prospective Clinical and Radiological Follow-Up Beyond 10 Years in Patellofemoral MACI (2024). (2024). https://doi.org/10.1177/2325967124s00196 https://doi.org/10.1177/2325967124s00196
2. [2] Patellar Dysplasia and Cell-Based Cartilage Repair Outcomes (2024). (2024). https://doi.org/10.1177/2325967124s00463 https://doi.org/10.1177/2325967124s00463